Literature DB >> 7151312

Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III.

O Nilsson, G Håkansson, S Dreborg, C G Groth, L Svennerholm.   

Abstract

A method was developed for the determination of cerebrosides in 1 ml of plasma or 1 ml of packed erythrocytes. At least 90% of the cerebroside fraction consisted of glucosylceramide. In the erythrocytes, nothing but glucosylceramide was identified. The method was applied to plasma samples from 25 controls, 34 Gaucher Type III obligate carriers, 16 Gaucher Type III patients, 7 Gaucher Type I patients and 7 patients with myelogenous or lymphatic leukemia, as well as to erythrocyte samples from 20 controls, 6 Gaucher Type III obligate carriers, 16 Gaucher Type III patients and 6 Gaucher Type I patients. The concentration of plasma cerebroside was 11.4 +/- 4.2 (S.D.) in controls, 11.8 +/- 2.6 in Gaucher Type III carriers, 30.4 +/- 7.7 in Gaucher Type III patients and 21.8 +/- 6.7 mumol/l in Gaucher Type I patients. The Gaucher patients had significantly increased (p less than 0.001) plasma cerebroside values, while the plasma cerebroside concentration of the leukemic patients was only slightly increased, 14.7 +/- 5.7 mumol/l. In the packed erythrocyte pellet the corresponding values were: Controls 2.9 +/- 0.7, Gaucher Type III carriers 2.9 +/- 0.7, Gaucher Type III patients 9.2 +/- 2.4 and Gaucher Type I patients 6.5 +/- 2.7 mumol/l. The phospholipid concentration was the same in all the three Gaucher groups and was not significantly different from that in the controls.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7151312     DOI: 10.1111/j.1399-0004.1982.tb01445.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  14 in total

Review 1.  The pathophysiology of GD - current understanding and rationale for existing and emerging therapeutic approaches.

Authors:  Derralynn A Hughes; Gregory M Pastores
Journal:  Wien Med Wochenschr       Date:  2010-12

2.  Reactions of vessel walls and brain parenchyma to the accumulation of Gaucher cells in the Norrbottnian type (type III) of Gaucher disease.

Authors:  N G Conradi; H Kalimo; P Sourander
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

3.  Unexpected macrophage-independent dyserythropoiesis in Gaucher disease.

Authors:  Nelly Reihani; Jean-Benoit Arlet; Michael Dussiot; Thierry Billette de Villemeur; Nadia Belmatoug; Christian Rose; Yves Colin-Aronovicz; Olivier Hermine; Caroline Le Van Kim; Melanie Franco
Journal:  Haematologica       Date:  2016-07-28       Impact factor: 9.941

4.  Late-infantile Gaucher disease in a child with myoclonus and bulbar signs: neuropathological and neurochemical findings.

Authors:  N Conradi; M Kyllerman; J E Månsson; A K Percy; L Svennerholm
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

5.  New macrophage models of Gaucher disease offer new tools for drug development.

Authors:  Daniel K Borger; Ellen Sidransky; Elma Aflaki
Journal:  Macrophage (Houst)       Date:  2015

6.  Changes in glucosylceramide structure affect virulence and membrane biophysical properties of Cryptococcus neoformans.

Authors:  Shriya Raj; Saeed Nazemidashtarjandi; Jihyun Kim; Luna Joffe; Xiaoxue Zhang; Ashutosh Singh; Visesato Mor; Desmarini Desmarini; Julianne Djordjevic; Daniel P Raleigh; Marcio L Rodrigues; Erwin London; Maurizio Del Poeta; Amir M Farnoud
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-09-01       Impact factor: 3.747

7.  Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies.

Authors:  N G Conradi; P Sourander; O Nilsson; L Svennerholm; A Erikson
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

8.  Optimal therapy in Gaucher disease.

Authors:  Ozlem Goker-Alpan
Journal:  Ther Clin Risk Manag       Date:  2010-07-21       Impact factor: 2.423

9.  Substrate compositional variation with tissue/region and Gba1 mutations in mouse models--implications for Gaucher disease.

Authors:  Ying Sun; Wujuan Zhang; You-Hai Xu; Brian Quinn; Nupur Dasgupta; Benjamin Liou; Kenneth D R Setchell; Gregory A Grabowski
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

Review 10.  Imiglucerase in the treatment of Gaucher disease: a history and perspective.

Authors:  Patrick B Deegan; Timothy M Cox
Journal:  Drug Des Devel Ther       Date:  2012-04-18       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.